Alector Initiates Phase 1 Clinical Trial of AL044 for the
Sep 12, 2022 · Alector Contacts: Martin Forrest VP, Investor Relations & Corporate Affairs 917-287-1584 [email protected]. 1AB (media) Dan Budwick 973-271-6085 ...
Alector Announces First Patient Dosed in PROGRESS-AD Phase
Feb 8, 2024 · About Alector Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases.
Alector Presents Preclinical Data from AL009 Multi-Siglec
Nov 12, 2021 · The poster is available on Alector website in the Investors section at www.alector.com. Alector management will also be conducting a call for analysts and investors to discussion data presented ...
Alector Announces First Participant Dosed in Phase 2 Study
Jan 25, 2021 · Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad ...
Alector Provides Executive Leadership Update - GlobeNewswire
Mar 28, 2025 · Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of ...
Alector Presents Baseline Characteristics for INVOKE-2
Jul 28, 2024 · Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura Perry 212.600.1902
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
Nov 25, 2024 · Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura Perry 212-600-1902
Alector Presents Results from First-in-Human Phase 1 Study
Nov 29, 2022 · Alector Contacts: 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura Perry/Carrie McKim Argot Partners 212.600.1902 [email protected].
Alector Presents Baseline Characteristics for Pivotal - GlobeNewswire
Sep 19, 2024 · Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient ...
Alector Reports on Recent Progress and Outlines Strategic
Jan 13, 2025 · Alector continues to advance its preclinical and research pipeline by leveraging its expertise in neuroscience and selectively applying its proprietary blood-brain barrier technology platform ...